← Back

Boltz

Series A · $110M

AI drug discovery startup that develops open-source and proprietary AI models to help pharmaceutical and biotech researchers design and evaluate drug candidates.

About Boltz

It has raised $110M in disclosed funding. FundFinder classes it as AI & ML.

Its investors also appear on FundFinder's most-active lists for Series A · Fintech (84 funds), Series A · B2B (81 funds), Series A · Generalist (63 funds).

Company facts from Harmonic and public filings; team backgrounds from public profiles. Refreshed weekly.

Want the latest on Boltz? Our research agent pulls the current description, latest round and full investor base from public sources (about a minute).

Series A · $110M · Nov 2026

  • Andreessen Horowitz — US based and global investors, Andreessen is a multi-stage investor with a number of portfolio services and a well known reputation in the industry
  • Hummingbird Ventures — Hummingbird Ventures was founded in Antwerp and is now based in London. · cheques £500k – £10M

Read the announcement ↗

Raising your own round? See which European funds fit →